WebMorisue R, Kojima M, Suzuki T, Nakatsura T, Ojima H, Watanabe R, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Ishii G, Gotohda N, Fujiwara T, Ochiai A. … Web11 nov 2012 · Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S, Nakatsura T (2011) HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 102:918–925
皮膚病態治療再建学講座
Web18 gen 2024 · Clinical successes demonstrated by chimeric antigen receptor T-cell immunotherapy have facilitated further development of T-cell immunotherapy against wide variety of diseases. One approach is the development of "off-the-shelf" T-cell sources. Technologies to generate T-cells from pluripotent stem c … Web14 feb 2013 · Nakatsura T Author information Affiliations 1 author 1. Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Japan; Department of Gastroenterological Surgery; Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences; Kita-ku, … grounded where to find pine cones
Generation of functional CD8+ T Cells by human dendritic cells ...
Web1 dic 2012 · Europe PMC is an archive of life sciences journal literature. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy]. Web17 gen 2024 · 45. Morisue R, Kojima M, Suzuki T, Nakatsura T, Ojima H, Watanabe R, et al. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. Int J Cancer (2024) 149(3):546–60. doi: 10.1002/ijc.33545. WebSuzuki T Shimomura M Fujinami N Nakatsura T. Journal volume & issue Vol. Volume 8 pp. 1035 – 1054 Abstract. Read online. Jimmy Charneau,1 Toshihiro Suzuki,1,2 Manami … fill in essay outline